From: Donald Rubin <~
Sent: Wednesday, December 7, 2016 3:38 PM
To: jeffrey E.
Subject: Re: Placebo effects, EB, etc.
Different ways to follow up.
1. The next time =hat we're in the same town, we could talk about the statistical =deas underlying ways to disentangle
placebo effects from biological =ffects of drugs and why that's important for FDA approvals and =or prescripts in the
docs office — different answers, I =hink.
2. =nbsp;l can send some recent things on the topic of placebo response, =hich are still not that wonderfully written.
3. If interested in exploring =nvesting in EB, I can put you in touch with Adriaan, who lives in =msterdam.
Are =ny of these appealing? I prefer 1 to 2. I think a face to =ace version of 3 could be arranged either here or there.
Let me =now.
On Dec 7, 2016, at 9:35 AM, jeffrey E. <jeevacation@gmail.com> wrote:
I'm always interested in unique idea
On =ed, Dec 7, 2016 at 10:12 AM Donald Rubin =rote:
Hello =effrey,
I'm glad that Martin has put us in touch for = couple of reasons. First, I think we have some mutual
interests =oncerning the complications of doing experiments with humans, rather =han plants or animals or tires. One
complication is noncompliance =ith the assigned treatment, which we briefly discussed at the dinner, =ut the more
interesting one is the placebo effect, which can be =igantic, for example in "viagra" type studies, which we =idn't get
around to discussing except indirectly in the context =f the Emotional Brain (EB) female viagra issue.
More generally, this is related to FDA standards for =pproving drugs. A slight aside: in January I'm one
of =hree people getting honorary degrees from the Medical Faculty of the =niversity of Uppsala in Sweden, where one of
the others is Robert =aliff, the current Commissioner of the FDA (the other is Marcia McNutt, =he current President of
the National Academy of Sciences), so I should =et the chance to bend his ear at various meals (a former commissioner
=E2$4 under Bush II — was a partial PhD student of mine when =e was getting his MD at Harvard and his PhD in Econ
at MIT, and remains = good friend: Mark McClellen, who is interested in this stuff and =emains quite influential in DC, I
think).
But the reason for rambling about the FDA and =lacebo effects is the following. This morning I just had
an =xchange of emails with the CEO of EB, whom I've known and =orked with for about three years, Adriaan Tuiten. He
wrote that =DA has agreed with EB's proposal for more trials, and the EB =oard of directors just approved the issuance
of about 12 million Euros =n stock to pay for these trials. Adriaan thinks that they may =ave enough connections now,
EFTA_R1_00108986
EFTA01786277
but would you be interested in =articipating? I already have some stock, which I earned though =onsulting. I think EB is
interesting but still needs more wisdom =hen it comes to their statistics (I've been to FDA with them =wo or three times,
and I think they still need help with some of their =deas e.g., using SNPs). If interested in tossing some money their =ay,
let me know.
In any case, I very =uch enjoyed our last conversations, and I look forward to seeing you =gain, either in
Cambridge or in NYC, which I'll probably get to =n the next couple of weeks.
Best wishes, =on
Donald B. Rubin
John L. Loeb Professor of Statistics
Department of Statistics, Harvard University
1 Oxford Street
Cambridge MA =2138
617-495-5498
On Dec 2, 2016, at 9:41 AM, =effrey E. <jeevacation@gmail.com
<mailto:jeevacation®gmail.com» =rote:
great
On Fri, Dec 2, =016 at 9:40 AM, Donald Rubin wrote:
Great, thanks Martin. Sometime when I get to NYC, which = often do to visit Columbia
connections, I'd like to be in =ouch, and give Jeffery more lectures in statistics — I think he =as some potential!
Also, =artin, should we try to touch base on Monday? The rest of the =eek is pretty
much shot for me with visitors.
2
EFTA_R1_00108987
EFTA01786278
Best, Don
> On Dec 2, 2016, =t 9:32 AM, Nowak, Martin A. < • wrote:
> Don , Jeffrey
> I would like to =ut you in direct email contact.
>=also cc =.
>_
3
EFTA_R1_00108988
EFTA01786279
please =ote
The information =ontained in this communication is
confidential, =ay be attorney-client privileged, may
constitute =nside information, and is intended only for
the =se of the addressee. It is the property of
JEE
Unauthorized use, disclosure or copying of this
communication or any part thereof is strictly =rohibited
and may be unlawful. If you have =eceived this
communication in error, please =otify us immediately by
return e-mail or by =-mail to jeevacation@gmail.com <mailto:jeevacation@gmail.com> , and
destroy this communication and all copies =hereof,
including all attachments. copyright =all rights reserved
4
EFTA_R1_00108989
EFTA01786280